Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
20 sept. 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
10 sept. 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors
05 sept. 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11
26 août 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
22 août 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative...
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
21 août 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative...
UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
13 août 2024 16h06 HE
|
Firefly Neuroscience, Inc.
Firefly Neuroscience CEO Issues Letter to Stockholders
Following Closing of Merger and Listing on Nasdaq
Psychedelic Drug (Ketamine, Psilocybin) Research Report 2024: A Global $4.6 Billion Market by 2030 - Strategic Analysis, Trends, Forecasts and Competitive Analysis 2018-2023 & 2024-2030
24 juil. 2024 09h50 HE
|
Research and Markets
Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "Psychedelic Drug Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
Cicero Institute Applauds Grant's Pass SCOTUS Decision
28 juin 2024 10h34 HE
|
The Cicero Institute
Austin, TX, June 28, 2024 (GLOBE NEWSWIRE) -- Earlier this year, The Cicero Institute filed an amicus brief with the U.S. Supreme Court in City of Grants Pass, Oregon v. Johnson (2024). Today, we...
The BC Schizophrenia Society Calls on British Columbians to #StandAgainstStigma this National Schizophrenia and Psychosis Awareness Day
24 mai 2024 10h00 HE
|
BC Schizophrenia Society
VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- The British Columbia Schizophrenia Society (BCSS), a provincial non-profit organization dedicated to supporting individuals and families...